Vanguard Capital Management
IMUX icon

Vanguard Capital Management’s Immunic IMUX Stock Holding History

Vanguard Capital Management’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$5.32M Hold
571,561
– – ﹤0.01% 3058
2026
Q2 		$8.78M Buy
571,561
+57,729
+11% +$712K ﹤0.01% 2900
2026
Q1 		$5.7M Buy
+513,832
New +$4.6M ﹤0.01% 3005

Other funds holding IMUX

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Laurion Capital Management
Laurion Capital Management New York $6.21B AUM 32.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
Nantahala Capital Management
Nantahala Capital Management New Canaan, Connecticut $3.16B AUM 31.44% 1-Year Est. Return
Propel Bio Management
Propel Bio Management Los Angeles, California $189M AUM 71.31% 1-Year Est. Return
Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return

Vanguard Capital Management's IMUX Position: Q3 2026 in Review

Vanguard Capital Management held its Immunic (IMUX) position steady in Q3 2026 at 571,561 shares worth $5.32M. The position accounts for ﹤0.01% of the portfolio, ranked #3058.

Vanguard Capital Management first reported a position in IMUX in Q1 2026 and has held it in 3 quarters since. The position peaked at $8.78M in Q2 2026. 49 funds tracked by Wall St. Rank hold IMUX as of Q3 2026.

  • Vanguard Capital Management held 571,561 shares of Immunic worth $5.32M as of Q3 2026.
  • Vanguard Capital Management left its Immunic share count unchanged in Q3 2026.
  • Immunic made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3058 holding.
  • Vanguard Capital Management first reported a position in Immunic in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Immunic position peaked at $8.78M in Q2 2026.
  • 49 funds tracked by Wall St. Rank held Immunic as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.